Navigation Links
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
Date:1/9/2009

e and recent data show the OA market to be growing by three percent annually. At this rate the U.S. patient population will grow to 60 million by 2020.

About ESBATech's antibody fragment platform technology

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragment frameworks. ESBATech's unique, scientific approach to stabilize monomeric, single-chain antibody fragments (scFvs) using its proprietary fully-human antibody fragment frameworks has elucidated the drug-like properties of these proprietary scFvs. The company is advancing a pipeline of novel antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The Company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. The Company focuses on three franchises: ophthalmology, rheumatology and respiratory. In ophthalmology, the Company has successfully completed clinical Phase I development of ESBA105 administered topically via eye drops for inflammatory eye diseases.

Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI Partners. For more information about ESBAT
'/>"/>

SOURCE ESBATech AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
6. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
7. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
8. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ... six months ended June 30, 2015 and updated its ... earnings conference call this morning, August 4, 2015, at ... join the call by dialing (855) 582-8078. The conference ... , Year-to-date net revenues of $38.3 million, an increase of ...
(Date:8/4/2015)... , Aug. 4, 2015  Ironshore Pharmaceuticals & ... Restore Health, a company specializing in personalized medicine, ... clinical trial, designed to evaluate the safety and ... to treat Attention-deficit/hyperactivity disorder (ADHD). This is Restore,s ... Restore Health originally partnered with Ironshore in 2014 ...
(Date:8/3/2015)... WEST JORDAN, Utah , Aug. 3, 2015  BC ... Solutions has acquired Ohio Valley Medical Systems, one of ... MRI systems.  The addition of Ohio Valley Medical Systems ... to now include Hitachi MRI.   "We ... Mark Alvarez , President and CEO of BC Technical. ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2BC Technical Acquires Ohio Valley Medical Systems 2
... Clinical Trial to be Presented at Retrovirus ConferenceLEXINGTON, Mass., ... IDEV ) announced today that a National Institutes of ... received PRO 2000, the Company,s candidate vaginal microbicide for ... acquiring HIV infection than women who received a placebo ...
... The U.S. Agency for International Development (USAID) continues to ... in the midst of an expanding humanitarian crisis. An ... left the people of Zimbabwe in danger of other ... is supporting emergency Indoor Residual Spraying (IRS) to shore ...
Cached Medicine Technology:Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study 2Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study 3Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study 4Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study 5Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study 6USAID Provides Malaria Assistance to Zimbabwe 2
(Date:8/4/2015)... ... , ... Updated enrollment data on the top U.S. health plans, as collected ... http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. Based ... on the website’s “Data” section include:, , Top 25 U.S. ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a three year clinical ... rare eye disease that progressively causes blindness, were published on June 23, 2015 in ... results of the trial, the implant, more commonly known as the “bionic eye,” is ...
(Date:8/4/2015)... Miramar Beach, FL (PRWEB) , ... August 04, 2015 , ... ... people are living with psoriatic disease and its uncomfortable symptoms such as dry, itching, ... suffer from psoriasis bounce from medication to medication before they find what’s right for ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Loyola University New Orleans, ... RN to BSN and Master of Science in Nursing in Health Care ... from the Commission on Collegiate Nursing Education (CCNE), the nation’s foremost ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4
... have claimed that body's immune system can be used as ... cancer. //Patients whose immune system was enhanced by drugs lived ... ,Two research teams in the U.S. were able to improvise ... were presented at a conference on cancer research at Prague. ...
... be the latest in a series of outbreaks this ... //Still Perrigo Company, the world's largest manufacturer of generic ... At a cost of $2.9 million, the company has ... painkiller it made for retailers like CVS, Wal-Mart, and ...
... Stem cells have captured the imagination of the world as ... cajoled into restoring or rejuvenating debilitating organs. //Research carried ... reiterate this belief, by restoring sight in mice which suffered ... ,This amazing work, which was published in 'Nature', could be ...
... Deutsche Forschungsgemeinschaft (DFG), //called for review of the Stem Cell ... ,In a statement, the DFG said, 'The 2002 Stem ... key date regulation and the penalties established in the Stem ... new cell lines and, to a large extent, prevented from ...
... cancer and deaths from the disease are alarming. According to ... cancer have been reported in Canada and 8,500 deaths from ... is 140,000 cases and 55,000 deaths, as reported by the ... the numbers at 34,900 cases and 16,000 deaths. ...
... per week are protected from developing prostate cancer//, as the ... has revealed. , ,The study that is available online ... consuming omega-3 fatty acids in protecting against cardiovascular disease (CVD), ... positively impact mood and behavior. ,Nearly half a million ...
Cached Medicine News:Health News:New Treatment For Skin Cancer Using Body's own Immune System 2Health News:Voluntary Recall Of Tainted Painkillers 2Health News:Research 'Extraordinaire' To Restore Vision 2Health News:German Scientists Call For Review Of Stem Cell Act 2
... T is a quadripolar pacing ... pacing and monitoring during and ... 227 T features tines for ... allows safe and easy implantation ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: